Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case series, three patients with advanced non-small cell lung cancer experienced severe skin eruptions and scarring alopecia after treatment with amivantamab, highlighting the critical need for prompt recognition and management of these adverse effects to minimize treatment interruptions.

In this mouse study, applying a vasoconstrictor before chemotherapy did not create a leukemia sanctuary or significantly impact survival outcomes, suggesting it may not interfere with leukemia treatment.

This abstract contains no research results; it provides information about the JAMA Dermatology journal and its access options.

RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.

This report describes a case where a 44-year-old male treated with vorasidenib for diffuse low-grade gliomas developed unexpected hair growth, including in areas of severe hair loss, after one month, highlighting a previously undocumented side effect.

This review suggests that a dual treatment approach using Nourella® cream with nano-encapsulated Retilex-A® and per-oral Vercilex® tablets may effectively improve skin thickness, elasticity, and overall rejuvenation in aging skin, as shown in interventional studies.

This article discusses the use of Espumil foam base in pharmacies for preparing dermatological medications and reports no new clinical results.

This article discusses the discontinuation of the Bexxar regimen for non-Hodgkin's lymphoma, noting that despite its effectiveness, it was under-prescribed due to marketing and development challenges without reporting new clinical results.

This research found that combining a 308-nm excimer laser with oral compound glycyrrhizin and topical 0.03% tacrolimus was more effective for treating pediatric facial and cervical vitiligo, resulting in faster and higher rates of repigmentation with minimal adverse effects compared to glycyrrhizin and tacrolimus alone.

This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.

This study found that venous blood ammonia levels, particularly in patients taking valproate combined with other antiepileptic drugs, were significantly elevated compared to those on valproate alone.

In a mouse model study, transcutaneous auricular vagus nerve stimulation (taVNS) significantly reduced depigmentation in vitiligo, potentially through mechanisms that regulate oxidative stress and inflammation, indicating taVNS's promise as a therapeutic approach for this skin disorder.

This source describes vitiligo as a chronic condition marked by the loss of skin pigmentation and discusses leukotrichia, a feature affecting 10% to 60% of cases, which arises from melanocyte loss in hair follicles and appears as well-defined white patches on the skin.

This study found that in noise-exposed FVB/NJ mice and cell models, ivacaftor reduced oxidative stress and hearing damage by maintaining CFTR function and increasing Nrf2 expression, suggesting its potential for treating noise-induced hearing loss.

This study found that the novel drug VDC-1101 showed a 45% objective response rate in treating canine cutaneous T-cell lymphoma, offering a potential treatment option for this challenging disease.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

This study found that combining α 1A-blockers with Prozac was more effective for treating premature ejaculation than using Prozac alone.

This review discusses using extracellular vesicles as less invasive surrogates for assessing drug-metabolizing enzymes and transporters, suggesting potential advancements in precision therapy, but reports no new clinical results.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.

This study found that VYC-15L (Juvéderm Volbella XC) was safe and effective for enhancing lip and perioral areas, achieving higher lip fullness improvement and fewer severe injection site reactions compared to NASHA, with effects lasting up to one year.

This study reports that a novel Nano-Structured Lipid Carrier system for delivering dutasteride may enhance its anticancer effects while reducing systemic side effects in clinical settings.

In this report, a 61-year-old woman with vitiligo showed significant improvement after tofacitinib treatment but developed lung adenocarcinoma, highlighting potential cancer risks associated with JAK inhibitors.

In this study, researchers found that niosomes, bilosomes, and spanlastic formulations can enhance the oral anticoagulation efficiency of rivaroxaban in rats, with spanlastic ranked as the most effective in prolonging clotting, prothrombin, and tail bleeding times compared to unprocessed rivaroxaban.

This study formulated and characterized a dutasteride-loaded nanocrystalline suspension for long-acting parenteral delivery, finding that it provided sustained drug release in rats with a significant reduction in local inflammation over 28 days following intramuscular injection.